业绩总结 - 2024年上半年总收入为2.356亿美元，较2023年同期的0.203亿美元增长了约103.4%[5] - 2024年第二季度产品收入为6590万美元，较2023年同期的2270万美元增长了约189.9%[5] - 2024年上半年调整后EBITDA为6350万美元，较2023年同期的-250万美元显著改善[5] - 2024年上半年里程碑收入为1.697亿美元，较2023年同期的-1.467亿美元大幅提升[5] - 2024年上半年产品收入为6600万美元，主要来自于Humira和Stelara生物类似药的推出[21] - 2024年上半年调整后的EBITDA为6400万美元，而去年同期为负1.47亿美元[21] - 截至6月30日，现金及流动性为1.78亿美元，其中包括2500万美元的限制性现金[21] - 2024年6月30日的总债务为9.65亿美元[20] 未来展望 - 预计到2025年底，至少将实现70个独特的产品上市[7] - 2024年预计将有3个生物制剂许可申请提交[7] - 2024年预计在多个市场提交至少3个生物类似药的申请[23] - 2024年总收入预计在4亿到5亿美元之间[23] - 2024年调整后的EBITDA预计在1亿到1.5亿美元之间[23] 新产品和技术研发 - AVT04在加拿大、美国和日本等关键市场的上市时间分别为2024年3月、2025年2月和2024年5月[14] - AVT02在美国的商业化协议已与Cigna网络的Quallent达成，预计在5周内将约20%的Cigna Humira客户转化为生物仿制药[11] - SIMLANDI®在Express Scripts等多个平台上被列为优先产品，预计2024年处方量将逐步增加[12] - 2024年将推出首个生物类似药JAMTEKI®，预计在美国于2025年2月上市[23] - 2024年制造产量较2023年增长超过3倍，尽管员工人数未增加[8]

Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023Product revenues for the first six months were $66 million, a 190% increase from the same period last year, with Q2 product revenues contributing $53 millionLicense and other revenues for the first six months increased to $170 million, with Q2 license and other revenues contributing $145 millionAdjusted EBITDA in the first six months was $64 million, compared to negative ($147) mi ...

Alvotech _____________________ Unaudited Condensed Consolidated Interim Financial Statements as of 30 June 2024 and 31 December 2023 and for the six months ended 30 June 2024 and 2023 Table of Contents | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------|-----------------| | Endorsement of the Board of Directors and the CEO | F-2 - F-6 | | Unaudited Condensed Consolidated Interim Statements of Profit or Loss ...

REYKJAVIK, Iceland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the year ended June 30, 2024, after U.S. markets close on Thursday, August 15, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Friday August 16, 2024, at 8:00 am EDT (12 noon GMT).   Live aud ...

REYKJAVIK, Iceland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the year ended June 30, 2024, after U.S. markets close on Thursday, August 15, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Friday August 16, 2024, at 8:00 am EDT (12 noon GMT).   Live au ...

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology1, dermatology and rheumatologyCreates competition at earliest opportunity, enabling straightforward switching to broaden patient access and control costs in a growing market, with accessible indications currently estimated at approximately €2.4 ...

Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology1, dermatology and rheumatologyCreates competition at earliest opportunity, enabling straightforward switching to broaden patient access and control costs in a growing market, with accessible indications currently estimated at approximately €2.4 billionUstekinumab is the second immunology biosimilar brought to market through the partnership betwee ...

文章核心观点 - 公司成功完成了1,035百万美元的优先担保贷款融资 [1][2][3] - 该融资将用于偿还现有债务、降低资本成本、改善债务到期情况 [1][2] - 公司现金余额为1.85亿美元,将用于推进现有管线和支持即将上市的生物类似药 [2] - 公司表示此次融资为其长期增长战略提供了更大灵活性 [4] 公司概况 - 公司专注于生物类似药的开发和制造 [5] - 公司已推出两款生物类似药,当前管线包括9款生物类似药候选药 [5] - 公司建立了广泛的全球商业合作伙伴网络,覆盖美国、欧洲、日本、中国等多个市场 [5] 财务情况 - 公司此次融资总额为9.65亿美元,包括9亿美元的优先担保贷款和6,500万美元的次级贷款 [3] - 优先担保贷款利率为SOFR+6.5%,次级贷款利率为SOFR+10.5% [3] - 融资将用于偿还现有债务,改善公司的债务到期情况 [1][2] - 公司现金余额为1.85亿美元,包括1,800万美元现金、2,500万美元受限现金和1.42亿美元净融资收入 [2] 未来展望 - 公司表示此次融资将为其长期增长战略提供更大灵活性 [4] - 公司将利用现金余额推进现有管线,支持即将上市的生物类似药 [2] - 公司表示此次可转债转股也显示了债券持有人对公司业绩和未来机遇的信心 [4]

REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facility (the “Facility”). The closing has allowed Alvotech to refinance outstanding debt obligations, reduce the cost of capital and improve its overall debt maturity profile. Following the closing of the Facility, whic ...

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endpointAlvotech expects to file marketing applications for AVT03 later this year for major global markets REYKJAVIK, Iceland, July 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development ...